CD38 and neoplasm: A detailed analysis of paired tumor biopsies from 11 patients revealed two subgroups defined by differences in CD38 upregulation following modakafusp alfa treatment, which was accompanied by differential intratumoral pharmacodynamic changes (Table 5, Figure 7).